Fantastic energy this week presenting preliminary findings from our SOLARA trial of BH-30643 in Boston. Please check out the poster which is now on the BHT pipeline website! Study enrolling full steam ahead with a focus on on-target resistance and TKI-naive #EGFR-mutant NSCLC.

Today, we announced the closing of an $84 million financing to accelerate our clinical-stage pipeline of intelligently designed #cancer medicines. Learn more from our Executive VP & CFO, Jason Keyes, below, & here: https://t.co/npk37XjgB4

We're on the road to present at the @GuggenheimSec 2nd Annual Healthcare Innovation Conference in Boston and also attending the #JeffriesHealthcare Global Conference in London, where we’ll be taking 1x1 meetings to discuss our science and pipeline. See you there!

Hi friends, it's #LungCancer Wednesday. Here are Top Posts of the Week! 🧵 1/ @geoff_oxnard on the preliminary findings of BH-30643 in NSCLC with EGFR and/​or HER2 mutations (SOLARA): https://t.co/jq6kbY1snj

Exciting early #SOLARATrial data from BH-30643 @ #AACR-#NCI-#EORTC showing tumor reductions & potential to overcome resistance in #EGFR-mutant #NSCLC. W/ its novel macrocyclic design, BH-30643 has potential to make a leap forward in #oncology innovation. https://t.co/KzxPCMxcPv

We’re excited to present @ AACR-NCI-EORTC International Conference w/ preliminary findings from the dose escalation portion of our ongoing, first-in-human Phase 1/2 SOLARA trial of BH-30643, a first-in-class, macrocyclic, non-covalent, OMNI-EGFR™. https://t.co/NVWemXhA13

@hiba_narvel @BalazsHalmosMD @lungoncdoc @BrunaPellini @IntegrityCE @aadel_chaudhuri @Latinamd @FawziAbuRous @chulkimMD @StephenVLiu @Joshua_Reuss @drgandara @COlazagasti @JCO_ASCO @theOncologist #tumorboardtuesday 🙏Thank you so much @BrunaPellini and @hiba_narvel for broadening our understanding of how we can get the best NGS results - blood, tissue, pleural fluid - etc That was enlightening😀

Honoring Bonnie J. Addario 🤍 We mourn the loss of Bonnie, who turned her own lung cancer diagnosis into a movement for change. Her foundation was the first to partner with us, funding EGFR research projects & giving us momentum. Her legacy lives on in every life she has touched

Bonnie Addario was an incredible champion for individualized lung cancer care. Her belief in me made a formative impact on my development as a lung cancer researcher. And the sea change she catalyzed - we will all persevere in pushing it forward! Memory eternal, Bonnie

We are very excited to announce the first patient dosed in the expansion cohorts of our #Solara trial studying BH-30643! "Our goal at #BlossomHill is to make the next leap forward in the...

How common is rebiopsy after progression on targeted therapy for NSCLC? Report @ClinicalLung included 148 pts with EGFR, ALK, and ROS1 NSCLC post TKI and 53% had rebiopsy - 47% tissue, 33% liquid, 20% both. Biopsy gave new information for 40% of pts. https://t.co/wmoBit4XxE

It's that time! If you are a fellow, Jr faculty, or post doc doing research in #EGFR #lungcancer, submit your abstract for a chance to join us in Chicago, Nov 6-8, at the @EGFRResisters Research Summit. Great opportunity to network with thought leaders in #lungcancer, other

🆕 #ASCO25 🆙 ☑️#LCSM Poster 🔥SOLARA: Phase 1/2, FIH study of BH-30643 in pts with NSCLC harboring EGFR and/or HER2-m 🎙️ @LeXiuning @HHorinouchi 📌Poster Bd135a, Abstr TPS 8663 🔢NCT06706076 @OncoAlert @ASCO @EGFRResisters @Larvol https://t.co/Lt4H1YyMzR

☑️#ASCO25 Abstract🆙 ☑️#LCSM Poster 🔥A phase 1/2, first-in-human study of the safety, tolerability, PK, and efficacy of BH-30643 in pts with locally advanced or metastatic NSCLC harboring EGFR and/or HER2-m (SOLARA) 🎙️ @LeXiuning @HHorinouchi 📌Poster Bd135a, Abstr TPS8663

#BlossomHill is looking forward to educating the #pharma community on our non-covalent, macrocyclic, mutant-selective OMNI-EGFR inhibitor, BH-30643, at #ASCO25 with two posters!! See you in Chicago! Links: https://t.co/9TLRTqd5J3 https://t.co/cEDJcnACCb #EGFR #NSCLC #cancer

🫁 Acquired resistance and therapeutic strategies for advanced #EGFR mutated #NSCLC ⭐️ The Model for figure is @geoff_oxnard #egfr #NSCLC #lungcancer #LCSM

Thrilled to meet friends @AACR2025 and be inspired by their work! @VivekSubbiah @ANaingMD @geoff_oxnard @DrHaddadRobert @HeadNeckMD @SGoswamiMDPhD @DrChoueiri @Phari

Excited to present our poster today at #AACR25 on the design and discovery of our new OMNI-EGFR inhibitor, BH-30643. To learn more, please stop by the poster this afternoon (S20, B18) or download the poster from our pipeline website at https://t.co/RRyrhsr1eC.

I just heard huge news that needs to be celebrated! Today marks 40 years of research and care for Dr Mark Kris @MSKCancerCenter Dr Kris has been a champion for innovative research, playing a pivotal role in many advancements over the past 4 decades. His contributions to science

Do you have a germline EGFR mutation? Would you like to join a nationwide study that will help us better understand genetic causes of lung cancer? Find out if you’re eligible for our study at https://t.co/owunflm2Se.